Lamda Therapeutics is a pre-clinical phase start-up developing an innovative approach for the treatment of diabetes harnessing a natural control mechanism preventing adipose tissue inflammation and insulin resistance.
Our vision is to improve the treatment of diabetes and related cardiometabolic disorders by targeting a major disease mechanism that is not affected by existing medication.
Lamda Therapeutics was founded in January 2020 by leading experts in the field of immunology, immunotherapy and endocrinology, Evangelos Andreakos, Research Director at the Biomedical Research Foundation of the Academy of Athens and Visiting Professor at Imperial College London, Maria Salagianni, Senior Researcher at the Biomedical Research Foundation of the Academy of Athens, and Gregory Kaltsas, Professor at the University of Athens Medical School and Executive Committee member of the International Society of Endocrinology (represeting >40.000 endocrinologists worldwide).
The company is developing an innovative therapy for the treatment of diabetes aiming at modulating adipose tissue inflammation, a major cause of insulin resistance and type 2 diabetes. This stems from years of research from the founders identifying a novel natural mechanism controlling immune system homeostasis at the adipose tissue which, when disturbed or inactivated, leads to chronic low grade adipose tissue inflammation causing obesity, insulin resistance and type 2 diabetes. The Lambda Therapeutics approach thus focuses on the development and administration of novel first-in-class molecules to restore normality at the adipose tissue, benefitting diabetic patients (both type 1 and type 2 diabetics) as well as a broad spectrum of patients with cardiometabolic and other diseases.
Evangelos Andreakos is Research Director at the Biomedical Research Foundation of the Academy of Athens and Visiting Professor at St Mary’s Hospital, National Heart and Lung Institute, Imperial College London. He holds a BSc and PhD degree from Imperial College London and has 67 publications with ~5.000 citations and >8M competitive grants and pharmaceutical industry funding as P.I. He has spent over 8 years at the Kennedy Institute of Rheumatology (London) in research with Prof. Sir Marc Feldmann, the discoverer of the anti-TNF therapy (Remicade, Embrel, Humira) making $35 billion per year in sales. He has also been involved in the setting up Synovis Ltd, a start-up founded by Prof. Sir M. Feldmann and colleagues. He is a leading expert in cytokine biology, immunology and immunotherapy with a strong translational focus.
Gregory Kaltsas is Professor of General Medicine and Endocrinology at the University of Athens Medical School and Visiting Professor at Warick University. He is a world-leading endocrinologist and clinical researcher with >290 publications and ~16.000 citations, and a regular advisor of pharmaceutical companies. He is also an Executive Committee Member of the International Society of Endocrinology (with >40.000 endocrinologists worldwide). He has strong knowledge of the science, research and management of diabetes.
Maria Salagianni is a Senior Researcher at the Biomedical Research Foundation of the Academy of Athens. She is an immunologist with a PhD from Kings College, University of London, and has unique know-how in preclinical animal models of obesity, diabetes and cardiometabolic diseases.
Lamda Therapeutics is developing an innovative approach for the treatment of diabetes aiming at the modulation of adipose tissue inflammation. This stems from years of research from the founders identifying a major natural mechanism controlling immune homeostasis at the adipose tissue which, when disturbed or inactivated, leads to chronic low grade adipose tissue inflammation causing obesity, insulin resistance and diabetes.
The Lamda Therapeutics approach thus focuses on the development and administration of fully human biologicals triggering this pathway to restore normality in the adipose tissue and treat patients in need. These include patients with type 2 diabetes poorly controlled by current medication (up to one third of all diabetic patients or 140 million) and that will eventually require insulin injections. Patients already receiving insulin (both type I and II diabetics) also constitute major target groups. The total accessible market is estimated at ~45 billion USD and is projected to rise in the coming years. The whole idea and application for diabetes, obesity and cardiometabolic diseases is covered by strong I.P. with more patents in preparation.
Lamda Therapeutics launched in January 2020.